BioSpace News Archive

Resverlogix Corp. (“Resverlogix”, or the “Corporation”) (TSX:RVX) today held its Annual and Special Meeting of Shareholders (the “Meeting”) in Calgary, Alberta. During business proceedings at the Meeting, shareholders elected six (6) Board members until the next annual meeting. The voting results of shares represented at the Meeting for individual directors were as follows: Votes For Votes Withheld

Met primary endpoint with robust statistical significance Showed efficacy on both hyperactivity/impulsivity and inattention subscales with statistical significance Showed statistically significant onset of action as early as week 2 Had a good safety and tolerability profile throughout the study Topline data confirm positive results from prior Phase IIa study in adults and Phase III studies of SPN-812 in children and adolescents

Inhibikase Therapeutics, Inc. (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics for Parkinson’s disease and related disorders that arise inside and outside of the brain, announced today the pricing of its initial public offering of 1,800,000 shares of common stock at a public offering price of $10.00 per sha

Transcenta Holding Limited, a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announces the completion of a 105 million USD crossover financing.

Annual Meeting to be adjourned solely with respect to Item 2, and Item 2 to be modified to decrease the proposed aggregate number of shares of common stock that the Company would be authorized to issue from 500,000,000 shares to 400,000,000 shares

Agilent Technologies Inc. announced it has obtained clearance from the Ministry of Health, Labour and Welfare in Japan for the GenetiSure Dx Postnatal Assay – a microarray-based assay for diagnostic use.

Innovent Biologics, Inc. announces that SULINNO®, a recombinant human anti-TNF-α monoclonal antibody drug, has been officially approved by the National Medical Products Administration of China for two new indications, including the treatment of pediatric plaque psoriasis and non-infectious intermediate uveitis, posterior uveitis and panuveitis in adults who do not respond adequately to corticosteroids, require restraint of corticosteroids, or are not suitable for corticosteroid therapies.

The Six-Month Contest Asked Global Innovators Between the Ages of 15-24 to Help Amid the Pandemic By Creating Face Mask Designs That Overcome Common Barriers to Use

Harvard Bioscience, Inc. announced the refinancing of its debt with the closing of a new $65 million credit facility.

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that an Emergency Use Authorization (EUA) Application has been submitted to the US Food and Drug Administration for its COVI-STIX rapid diagnostic test for the detection of the SARS-CoV-2 virus nucleocapsid antigen in nasal samples of patients.